Allergic rhinitis and asthma: Celebrating 100 years of immunotherapy

Current Opinion in Immunology

Volumn 23, Issue 6, 2011, Pages 808-813

  Stokes, Jeffrey R ^a   Casale, Thomas B ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; EPITOPE; HOUSE DUST ALLERGEN; IMMUNOMODULATING AGENT; MONTELUKAST; OMALIZUMAB; PLACEBO; PLANT ANTIGEN; RAGWEED ANTIGEN; RECEPTOR BLOCKING AGENT; RECOMBINANT ALLERGEN; TIMOTHY GRASS ANTIGEN; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC REACTION; ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; DRUG FORMULATION; DRUG MEGADOSE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LOW DRUG DOSE; PEANUT ALLERGY; PUBLICATION; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY;

ALLERGENS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; RHINITIS;

EID: 82955247942     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.07.015     Document Type: Review

References (51)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, 1:1572.
2. Ariano R., Canonica G.W., Passalacqua G. Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Ann Allergy Asthma Immunol 2010, 104:215-222.
3. Ziska L., Knowlton K., Rogers C., Dalan D., Tierney N., Elder M.A., Filley W., Shropshire J., Ford L.B., Hedberg C., et al. Recent warming by latitude associated with increased length of ragweed pollen season in central North America. Proc Natl Acad Sci USA 2011, 108:4248-4251.
4. Larenas-Linnemann D., Cruz A.A., Gutierrez I.R., Rodriguez P., Shah-Hosseini K., Michels A., Mösges R. European and Mexican vs US diagnostic extracts of Bermuda grass and cat in skin testing. Ann Allergy Asthma Immunol 2011, 106:421-428.
5. Moore M., Tucker M., Grier T., Quinn J. Effects of summer mailing on in vivo and in vitro relative potencies of standardized timothy grass extract. Ann Allergy Asthma Immunol 2010, 104:147-151.
6. Stillerman A., Nachtsheim C., Li W., Albrecht M., Waldman J. Efficacy of a novel air filtration pillow for avoidance of perennial allergens in symptomatic adults. Ann Allergy Asthma Immunol 2010, 104:440-449.
7. Bobb C., Ritz T., Rowlands G., Griffiths C. Effects of allergen and trigger factor avoidance advice in primary care on asthma control: a randomized-controlled trial. Clin Exp Allergy 2010, 40:143-152.
8. Spertini F., Berney M., Foradini F., Roulet C.A. Major mite allergen Der f 1 concentration is reduced in buildings with improved energy performance. Allergy 2010, 65:623-629.
9. Kuna P., Kaczmarek J., Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 2011, 127:502-508.e1-6.
10. Zielen S., Kardos P., Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010, 126:942-949.
11. Majak P., Rychlik B., Pułaski L., Błauz A., Agnieszka B., Bobrowska-Korzeniowska M., Kuna P., Stelmach I. Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma. J Allergy Clin Immunol 2010, 125:1220-1227.
12. Tabar A.I., Arroabarren E., Echechipía S., García B.E., Martin S., Alvarez-Puebla M.J. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011, 127:57-63. 63.e1-3.
13. Costa D.J., Amouyal M., Lambert P., Ryan D., Schünemann H.J., Daures J.P., Bousquet J., Bousquet P.J. How representative are clinical study patients with allergic rhinitis in primary care?. J Allergy Clin Immunol 2011, 127:920-926.e1. Languedoc-Roussillon Teaching General Practitioners Group.
14. Hankin C.S., Cox L., Lang D., Bronstone A., Fass P., Leatherman B., Wang Z. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010, 104:79-85.
15. Matricardi P.M., Kuna P., Panetta V., Wahn U., Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol 2011, [Epub ahead of print].
16. López S., Rondón C., Torres M.J., Campo P., Canto G., Fernandez R., Garcia R., Martínez-Cañavate A., Blanca M. Immediate and dual response to nasal challenge with Dermatophagoides pteronyssinus in local allergic rhinitis. Clin Exp Allergy 2010, 40:1007-1014.
17. Rondón C., Blanca-López N., Aranda A., Herrera R., Rodriguez-Bada J.L., Canto G., Mayorga C., Torres M.J., Campo P., Blanca M. Local allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen. J Allergy Clin Immunol 2011, 127:1069-1071.
18. Nelson H.S., Nolte H., Creticos P., Maloney J., Wu J., Bernstein D.I. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011, 127:72-80. 80.e1-2.
19. Blaiss M., Maloney J., Nolte H., Gawchik S., Yao R., Skoner D.P. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011, 127:64-71. 71.e1-4.
20. Durham S.R., Emminger W., Kapp A., Colombo G., de Monchy J.G., Rak S., Scadding G.K., Andersen J.S., Riis B., Dahl R. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010, 125:131-138.e1-7.
21. Frølund L., Durham S.R., Calderon M., Emminger W., Andersen J.S., Rask P., Dahl R. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010, 65:753-757.
22. Di Bona D., Plaia A., Scafidi V., Leto-Barone M.S., Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010, 126:558-566.
23. Skoner D., Gentile D., Bush R., Fasano M.B., McLaughlin A., Esch R.E. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 2010, 125:660-666. 666.e1-666.e4.
24. Bush R.K., Swenson C., Fahlberg B., Evans M.D., Esch R., Busse W.W. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011, 127:974-981.e1-7.
25. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010, 126:969-975.
26. Radulovic S., Wilson D., Calderon M., Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011, 66:740-752. 10.1111/j.1398-9995.2011.02583.x.
27. Brozek J.L., Bousquet J., Baena-Cagnani C.E., Bonini S., Canonica G.W., Casale T.B., van Wijk R.G., Ohta K., Zuberbier T., Schünemann H.J. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 126:466-476. Global Allergy and Asthma European Network; Grading of Recommendations Assessment Development and Evaluation Working Group.
28. Calderón M.A., Casale T.B., Togias A., Bousquet J., Durham S.R., Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011, 127:30-38. Erratum in: J Allergy Clin Immunol. 2011 Apr;127(4):859.
29. Agostinis F., Forti S., Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010, 65:410-411.
30. Worm M., Lee H.H., Kleine-Tebbe J., Hafner R.P., Laidler P., Healey D., Buhot C., Verhoef A., Maillère B., Kay A.B., Larché M. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011, 127:89-97. 97.e1-14.
31. Calabria C.W., Stolfi A., Tankersley M.S. The REPEAT study: recognizing and evaluating periodic local reactions in allergen immunotherapy and associated systemic reactions. Ann Allergy Asthma Immunol 2011, 106:49-53.
32. Cox L., Larenas-Linnemann D., Lockey R.F., Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010, 125:569-574. 574.e1-574.e7.
33. Bernstein D.I., Epstein T., Murphy-Berendts K., Liss G.M. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010, 104:530-535.
34. Confino-Cohen R., Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol 2010, 104:73-78.
35. Webber C.M., Calabria C.W. Assessing the safety of subcutaneous immunotherapy dose adjustments. Ann Allergy Asthma Immunol 2010, 105:369-375.
36. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., Nelson M., Weber R., Bernstein D.I., Blessing-Moore J., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(1 Suppl.):S1-S55. Erratum in: J Allergy Clin Immunol. 2011 Mar;127(3):840.
37. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011, 127:18-27. quiz 28-29. Review.
38. Tversky J.R., Bieneman A.P., Chichester K.L., Hamilton R.G., Schroeder J.T. Subcutaneous allergen immunotherapy restores human dendritic cell innate immune function. Clin Exp Allergy 2010, 40:94-102.
39. James L.K., Shamji M.H., Walker S.M., Wilson D.R., Wachholz P.A., Francis J.N., Jacobson M.R., Kimber I., Till S.J., Durham S.R. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011, 127:509-516.e1-5.
40. Ankerst J., Nopp A., Johansson S.G., Adédoyin J., Oman H. Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 2010, 152:71-74.
41. van den Berge M., Pauw R.G., de Monchy J.G., van Minnen C.A., Postma D.S., Kerstjens H.A. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011, 139:190-193.
42. Hanania N.A., Alpan O., Hamilos D.L., Condemi J.J., Reyes-Rivera I., Zhu J., Rosen K.E., Eisner M.D., Wong D.A., Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154:573-582.
43. Busse W.W., Morgan W.J., Gergen P.J., Mitchell H.E., Gern J.E., Liu A.H., Gruchalla R.S., Kattan M., Teach S.J., Pongracic J.A., et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011, 364:1005-1015.
44. Corren J., Wood R.A., Patel D., Zhu J., Yegin A., Dhillon G., Fish J.E. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. J Allergy Clin Immunol 2011, 127:398-405.
45. Rodrigo G.J., Neffen H., Castro-Rodriguez J.A. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011, 139:28-35.
46. Groffik A., Mitzel-Kaoukhov H., Magerl M., Maurer M., Staubach P. Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011, 66:303-305. 10.1111/j.1398-9995.2010.02472.x.
47. Sampson H.A., Leung D.Y., Burks A.W., Lack G., Bahna S.L., Jones S.M., Wong D.A. A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011, 127:1309-1310.e1.
48. Massanari M., Nelson H., Casale T., Busse W., Kianifard F., Geba G.P., et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010, 125:383-389.
49. Lin R.Y., Rodriguez-Baez G., Bhargave G.A. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009, 103:442-445.
50. Cox L., Lieberman P., Wallace D., Simons F.E., Finegold I., Platts-Mills T., Schwartz L. American Academy of Allergy, Asthma & Immunology/American College of Allergy Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011, 128:210-212.
51. Casale T.B., Stokes J.R. Future forms of immunotherapy. J Allergy Clin Immunol 2011, 127:8-15. quiz 16-17.